Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Rectal Neoplasms 2Neoplasms 2Waldenstrom Macroglobulinemia 1Prostatic Neoplasms 1Paraproteinemias 1Lung Neoplasms 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Specimen Handling 9Practice Guidelines as Topic 9Standard of Care 8Early Intervention, Educational 5Taxes 4Paclitaxel 4Docetaxel 4pertuzumab 3pembrolizumab 3Trastuzumab 3Methods 3Magnetic Resonance Spectroscopy 3Interviews as Topic 3Educational Status 3Biopsy 3trastuzumab biosimilar HLX02 2PF-05280014 2Ontruzant 2Ogivri 2Minoxidil 2Letrozole 2High-Energy Shock Waves 2Cyclophosphamide 2Carboplatin 2Acupuncture Therapy 22C4 antibody 2regadenoson 1palbociclib 1nilotinib 1lorcaserin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anatomic Stage I Breast Cancer AJCC v8 × Rifaximin × Clear all
NCT04249622 2025-09-16

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

Mayo Clinic

Phase 2 Terminated
20 enrolled 13 charts
Breast

Anatomic Stage I Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡